Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score

Study (n=61,338) found a higher number of patients should be considered for dual treatment based on 2019 ESC guidelines vs CHADS-P2A2RC score (33.9% vs 24.9%). Authors suggest CHADS-P2A2RC score enabled correct downward risk reclassification of 8% of patients.

SPS commentary:

Authors suggest the CHADS-P2A2RC score improved risk classification and may particularly identify low-risk patients with limited benefit from treatment.

European Heart Journal